Heron Therapeutics (HRTX) Receivables (2016 - 2025)
Historic Receivables for Heron Therapeutics (HRTX) over the last 11 years, with Q3 2025 value amounting to $81.0 million.
- Heron Therapeutics' Receivables rose 2089.53% to $81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.0 million, marking a year-over-year increase of 2089.53%. This contributed to the annual value of $79.1 million for FY2024, which is 3093.12% up from last year.
- Heron Therapeutics' Receivables amounted to $81.0 million in Q3 2025, which was up 2089.53% from $79.9 million recorded in Q2 2025.
- Heron Therapeutics' Receivables' 5-year high stood at $81.0 million during Q3 2025, with a 5-year trough of $35.7 million in Q4 2021.
- For the 5-year period, Heron Therapeutics' Receivables averaged around $58.9 million, with its median value being $60.4 million (2023).
- Per our database at Business Quant, Heron Therapeutics' Receivables plummeted by 1526.65% in 2021 and then surged by 9029.1% in 2023.
- Quarter analysis of 5 years shows Heron Therapeutics' Receivables stood at $35.7 million in 2021, then soared by 62.95% to $58.2 million in 2022, then rose by 3.78% to $60.4 million in 2023, then surged by 30.93% to $79.1 million in 2024, then increased by 2.4% to $81.0 million in 2025.
- Its Receivables stands at $81.0 million for Q3 2025, versus $79.9 million for Q2 2025 and $78.7 million for Q1 2025.